Antiangiogenic treatment with endostatin inhibits progression of AML in vivo

Leukemia

Volumn 19, Issue 8, 2005, Pages 1312-1317

  Schuch, G ^a   Oliveira Ferrer, L ^a   Loges, S ^a   Laack, E ^a   Bokemeyer, C ^a   Hossfeld, D K ^a   Fiedler, W ^a   Ergun, S ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

AML; Angiogenesis; Encapsulation; Endostatin

Indexed keywords

ANGIOGENESIS INHIBITOR; CD31 ANTIGEN; ENDOSTATIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CHLOROMA; CONTROLLED STUDY; DISEASE COURSE; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MICROENCAPSULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; SOMATIC GENE THERAPY; STATISTICAL SIGNIFICANCE; TUMOR VASCULARIZATION;

EID: 23744466261     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403824     Document Type: Article

References (45)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
2. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-674.
3. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
4. Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, Stockschlader M et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997; 89: 1870-1875.
5. Padro T, Bieker R, Ruiz S, Steins M, Retzlaff S, Bürger H et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 2002; 16: 1302-1310.
6. Aguayo A, Kantarjian HM, Estey EH, Giles FJ, Verstovsek S, Manshouri T et al. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer 2002; 95: 1923-1930.
7. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000; 95: 309-313.
8. Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000; 95: 2637-2644.
9. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D et al. Angiogenesis in acute and chronic leukemias and myelodysplastic disorders. Blood 2000; 96: 2240-2245.
10. Kozu I, Beksac M, Arat M, Celebi H, Elhan AH, Erekul S. Bone marrow microvessel density (MVD) in adult acute myeloid leukemia (AML): therapy induced changes and effects on survival. Leuk Lymphoma 2004; 45: 1185-1190.
11. Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001; 97: 1427-1434.
12. Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, Stockschlader M et al. Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia. Leukemia 1997; 11: 1234-1237.
13. Muller A, Lange K, Gaiser T, Hofmann M, Bartels H, Feller AC et al. Expression of angiopoietin-1 and its receptor TEK in hematopoietic cells from patients with myeloid leukemia. Leuk Res 2002; 26: 163-168.
14. Loges S, Heil G, Bruweleit M, Schroder V, Butzal M, Fischer W et al. Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: Expression of angiopoietin-2 represents an independent prognostic growth factor for overall survival. J Clin Oncol 2005; 23: 1109-1117.
15. Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000; 106: 511-521.
16. Wakabayashi M, Miwa H, Shikami M, Hiramatsu A, Ikai T, Tajima E et al. Autocrine pathway of angiopoietins-Tie2 system in AML cells: association with phosphatidyl-inositol 3 kinase. Hematol J 2004; 5: 353-360.
17. Schuch G, Machluf M, Bartsch Jr G, Nomi M, Richard H, Atala A et al. In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. Blood 2002; 100: 4622-4628.
18. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
19. Dhanabal M, Ramchandran R, Volk R, Stillman IE, Lombardo M, Iruela-Arispe ML et al. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res 1999; 59: 189-197.
20. Perletti G, Concari P, Giardini R, Marras E, Piccinini F, Folkman J et al. Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors. Cancer Res 2000; 60: 1793-1796.
21. Blezinger P, Wang J, Condo M, Quezada A, Mehrens D, French M et al. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat Biotechnol 1999; 17: 343-348.
22. Kisker O, Becker CM, Prox D, Fannon M, D'Amato R, Flynn E et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 2001; 61: 7669-7674.
23. Dhanabal M, Ramchandran R, Waterman MJ, Lu H, Knebelmann B, Segal M et al. Endostatin induces endothelial cell apoptosis. J Biol Chem 1999; 274: 11721-11726.
24. Kilic N, Ergun S. Methods to evaluate the formation and stabilization of blood vessels and their role in tumor growth and metastasis. In: Brooks SA, Schumacher U (eds.) Metastasis Research Protocols, Vol. 2, pp 125-148.
25. Ergun S, Kilic N, Wurmbach JH, Ebrahimnejad A, Fernando M, Sevinc S et al. Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes. Angiogenesis 2001; 4: 193-206.
26. Deckers M, van der Pluijm G, Dooijewaard S, Kroon M, van Hinsbergh V, Papapoulos S et al. Effect of angiogenic and antiangiogenic compounds on the outgrowth of capillary structures from fetal mouse bone explants. Lab Invest 2001; 81: 5-15.
27. Hanai J, Dhanabal M, Karumanchi SA, Albanese C, Waterman M, Chan B et al. Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem 2002; 277: 16464-16469.
28. Morbidelli L, Donnini S, Chillemi F, Giachetti A, Ziche M. Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin. Clin Cancer Res 2003; 9: 5358-5369.
29. Bruserud O, Glenjen N, Ryningen A. Effects of angiogenic regulators on in vitro proliferation and cytokine secretion by native human acute myelogenous leukemia blasts. Eur J Haematol 2003; 71: 9-17.
30. Bertolini F, Fusetti L, Mancuso P, Gobbi A, Corsini C, Ferrucci PF et al. Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. Blood 2000; 96: 282-287.
31. Capillo M, Mancuso P, Gobbi A, Monestiroli S, Pruneri G, Dell'Agnola C et al. Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin Cancer Res 2003; 9: 377-382.
32. Read TA, Sorensen DR, Mahesparan R, Enger PO, Timpl R, Olsen BR et al. Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat Biotechnol 2001; 19: 29-34.
33. Joki T, Machluf M, Atala A, Zhu J, Seyfried NT, Dunn IF et al. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat Biotechnol 2001; 19: 35-39.
34. Schuch G, Heymach JV, Nomi M, Machluf M, Force J, Atala A et al. Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res 2003; 63: 8345-8350.
35. Yi M, Sakai T, Fassler R, Ruoslahti E. Antiangiogenic proteins require plasma fibronectin or vitronectin for in vivo activity. Proc Natl Acad Sci USA 2003; 100: 11435-11438.
36. Kisker O, Becker CM, Prox D, Fannon M, D'Amato R, Flynn E et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 2001; 61: 7669-7674.
37. Abdollahi A, Hahnfeldt P, Maerker C, Grone HJ, Debus J, Ansorge W et al. Endostatin's antiangigenic signaling network. Mol Cell 2004; 13: 649-663.
38. Kim YM, Hwang S, Kim YM, Pyun BJ, Kim TY, Lee ST et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 2002; 277: 27872-27879.
39. Wickstrom SA, Alitalo K, Keski-Oja J. Endostatin associates with integrin alpha5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res 2002; 62: 5580-5589.
40. Eisterer W, Jiang X, Bachelot T, Pawliuk R, Abramovich C, Leboulch P et al. Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia. Mol Therapy 2002; 5: 352-359.
41. Iversen PO, Sorensen DR, Benestad HB. Inhibitors of angiogenesis selectively reduce the malignant cell load in rodent models of human myeloid leukemias. Leukemia 2002; 16: 376-381.
42. Miyake K, Inokuchi K, Miyake N, Dan K, Shimada T. Antiangiogenic gene therapy of myeloproliferative disease developed in transgenic mice expressing P230 bcr/abl. Gene Therapy 2005; 12: 541-545.
43. Scappaticci FA, Smith R, Pathak A, Schloss D, Lum B, Cao Y et al. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice. Mol Therapy 2001; 3: 186-196.
44. Fiedler W, Mesters R, Tinnefeld H, Loges S, Staib P, Duhrsen U et al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 2003; 102: 2763-2767.
45. Karp JE, Gojo I, Pili R, Gocke CD, Greer J, Guo C et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res 2004; 10: 3577-3585.